+

WO1996015232A1 - Nouveau procede de replication - Google Patents

Nouveau procede de replication Download PDF

Info

Publication number
WO1996015232A1
WO1996015232A1 PCT/US1995/014814 US9514814W WO9615232A1 WO 1996015232 A1 WO1996015232 A1 WO 1996015232A1 US 9514814 W US9514814 W US 9514814W WO 9615232 A1 WO9615232 A1 WO 9615232A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
cells
vero
trypsin
influenza
Prior art date
Application number
PCT/US1995/014814
Other languages
English (en)
Inventor
Robert G. Webster
Nicolai V. Kaverin
Original Assignee
St. Jude Children's Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St. Jude Children's Research Hospital filed Critical St. Jude Children's Research Hospital
Priority to AU41589/96A priority Critical patent/AU694592B2/en
Priority to JP8516287A priority patent/JPH11509081A/ja
Priority to EP95939952A priority patent/EP0808361A4/fr
Priority to NZ296861A priority patent/NZ296861A/en
Publication of WO1996015232A1 publication Critical patent/WO1996015232A1/fr
Priority to NO972239A priority patent/NO972239L/no
Priority to CA002205677A priority patent/CA2205677A1/fr
Priority claimed from CA002205677A external-priority patent/CA2205677A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Definitions

  • This invention relates to a process for viral replication in mammalian cells and particularly viral replication of human influenza virus in Vero cell culture.
  • HA hemagglutinin
  • the major influenza virus glycoprotein hemagglutinin (HA)
  • HA hemagglutinin
  • Post- translational cleavage of the HA forms two subunits, HA1 and HA2, joined by a disulfide bond. Cleavage is essential to the production of infectious virus; virions containing uncleaved HA are non-infectious. The process can occur intracellularly or extracellularly.
  • the HAS of human, swine, and most avian influenza virus strains cannot be cleaved by ubiquitous intracellular proteases.
  • influenza viruses grown in mammalian cells possess structurally homogenous hemagglutinin molecules (Has) that are identical to the predominant Has of the original clinical isolate [Katz et al, Virology, Vol. 165 (1988), pp. 446-456; Robertson et al, Virology, Vol. 179 (1990), pp. 35-40].
  • influenza viruses grown in mammalian cells elicit neutralizing and hemagglutinin inhibition (HI) antibodies in human sera more readily and at higher titers than do their egg-grown counterparts.
  • MDCK Madin-Darbin canine kidney
  • Influenza viruses can be propagated in several types of primary cell cultures including chick embryo kidney, chick embryo lungs, monkey kidney, canine kidney, bovine kidney, chick kidney, guinea pig kidney, and chick embryo fibroblasts.
  • primary tissue cultures are unlikely to be useful as a substrate for vaccine production for several reasons, including contamination by various endogenous agents, the variable quality of the cells, different sensitivities to variants of the same virus, and, of course, high cost and difficulties in obtaining and preparing the tissue cultures.
  • Diploid tissue cultures such as WI-38, have been used to produce vaccines against poliomyelitis, adenovirus types 4 and 7, rubella, measles, and rabies viruses.
  • human diploid (MRC-5) cells can support the growth of influenza viruses, such systems have stringent growth media requirements and are expensive to maintain, making them suboptimal for large-scale production of vaccines. Disclosure of the Invention
  • This invention of a process for ensuring replication of human influenza virus at a low multiplicity of infection in a mammalian cell line involves maintaining a consistent minimum concentration of trypsin (about 0.05 ⁇ g/ml) in the culture medium.
  • Vero cells are sensitive to a spectrum of viruses, including: enteroviruses, measles and parainfluenza viruses, herpes viruses, andenoviruses, rhabdoviruses and some arboviruses. Low-passage- number Vero cells lack tumorigenicity, do not contain adventitious viruses and can support efficient proliferation of many types of viruses. This cell line has been used successfully for the production of vaccines against poliomyelitis and rabies. The Vero cell line is suitable for cultivation of infectious influenza A viruses and for primary isolation of currently circulating influenza A (H3N2) strains.
  • H3N2 currently circulating influenza A
  • H1N1 influenza A/England/1/53 [HG] strain to Vero cell culture, its growth characteristics and antigenic stability, and the likelihood of obtaining high yields of viral proteins with Vero is compared to MDCK cells.
  • Vero (WHO) cells When infected with influenza A virus at a multiplicity of at least 0.005 TCID 50 per cell, Vero (WHO) cells produced yields of virus comparable to those produced in Madin-Darby canine kidney (MDCK) cells. However, at lower multiplicities of infection, multicycle growth was blocked early in the course of infection, the progress of the cytopathic effect was stopped, and the final virus yields were low.
  • MDCK Madin-Darby canine kidney
  • trypsin concentrations of at least 0.05 ⁇ q/ml in the cell culture were essential for securing high virus yields and that a concentration of about 0.1 ⁇ g/ml was optimal when the multiplicity of infection ranged from about 1 ⁇ 10 -5 and 1 ⁇ 10 -6 TCID 50 per cell; satisfactory results were obtained at about 5 ⁇ 10 -7 TCID 50 Per cell.
  • trypsin had to be maintained from about 0.05 to 0.5 ⁇ g/ml to secure adequate yields of virus.
  • a higher volume of maintenance medium per area of cell monolayer also required slight improvement of multicycle virus growth at low input doses, most likely because of a lower concentration of trypsin-inactivating factor in the medium.
  • the trypsin- inactivating factor in cell cultures belongs to the class of proteins that inhibit proteinases
  • our findings of a putative inhibitor of trypsin activity may be of value in the studies of serine proteinase inhibitors.
  • the inhibitors of this family although numerous and extensively studied, are mostly derived from such substances as plants, bovine pancreas, human and animal plasma, tissues of invertebrate species, etc. For this reason, their structure in enzymological properties are far better known than their biosynthesis, intracellular transport and secretion mechanism. Thus, inhibitors produced by cultured cells may prove to be a valuable asset.
  • the best mode for carrying out the invention there are described several preferred embodiments to illustrate the invention. However, it is to be understood that the invention is not intended to be limited to the specific embodiments contained therein. Best Mode for Carrying Out the Invention
  • the Vero (WHO) cell line deposit no. 1297, was obtained from the American Type Tissue Collection at the level of the 134th passage.
  • the cells were cultivated as monolayers in Falcon Labware 250 cm 3 flasks at 37°C and 5% Co 2 in a growth medium of Eagles minimal essential medium (MEM) supplemented with 10% unheated fetal calf serum.
  • MEM Eagles minimal essential medium
  • MDCK Madin-Darby canine kidney
  • LLC-MK 2 rhesus monkey kidney
  • the medium used was MEM with 5% fetal calf serum heated 30 minutes at 56°C.
  • RPMI 1640 medium was used with 5% heated fetal calf serum.
  • the cells were grown either in 50 cm 3 flasks or in 6-well, 24-well, and 96-well plates (Falcon Labware). Cell monolayers were washed three times with PBS and overlaid with maintenance medium. The latter had the same composition as the growth medium for each cell line, the serum being omitted and 0.3% bovine serum albumin (BSA) added. Unless otherwise stated, the maintenance medium contained TPCK-trypsin (Worthington) at 1.0 ⁇ g/ml. Plaque assays were performed with TPCK-treated trypsin (2.5 ⁇ g/ml).
  • Vero (WHO)-adapted influenza A/England/1/53 (H1N1) [HG], A/FW/1/50 (H1N1), and A/Aichi/2/68-PR/8/34 (H3N2) [X-31] viruses were used. The viruses were passaged 5 times in Vero (WHO) cell cultures, and the final stock virus preparations contained about 10 7.3 to 10 8.25 TCID 50 /0.2 ml and about 32 to about 128 HAU. In the preliminary experiments, the Vero (WHO)-adapted A/Rome/49 (H1N1) strain was used (10 6.7 TCID 50 /0.2 ml, about 15 to about 32 HAU).
  • HA and infectivity titration were performed essentially as described in "Advanced Laboratory Techniques for Influenza Diagnosis" [Immunol. Ser. 6, pp. 51-57 (1975)]. HA titrations were done in mirotiter plates. Infectivity was measured by an end point titration technique in MDCK cells grown in 96-well plates with CPE evaluation at 72h postinfection.
  • BAAMC Na-benzoyl-L- arginine-7-amido-4-methylcoumarin-hydro-chloride
  • the substrate was dissolved to a final concentration of about 0.2 Mm in a buffer containing 50 Mm of Tris-Hcl, Ph about 8.0, 10 Mm CaCl 2 and 1% DMSO.
  • a 0.1 ml sample of trypsin-containing cell culture fluid was added to about 0.9 ml of BAAMC solution and incubated at 37°C for 1 hour. The samples were placed on ice and assayed in a Perkin-Elmer MPF-44B fluorescence spectrophotometer at activation and emission wavelengths of about 380 and 460 nm, respectively.
  • Vero cells were infected with the A/England/1/53 (H1N1) [High Growth, HG] strain of influenza virus, a reassortant containing the gene segments coding for the two surface glycoproteins (HA and NA) from A/England/1/53 (H1N1) and the remaining six genes from A/PR/8/34 (H1N1).
  • H1N1 A/England/1/53
  • HA and NA two surface glycoproteins
  • H1N1N1 the virus was left to adsorb for 1 hour at 37°C, after which the monolayer was washed twice with warm phosphate buffered saline (PBS) solution to remove the unadsorbed viruses.
  • PBS phosphate buffered saline
  • Serum-free MEM with 0.3% bovine serum albumin (BSA) was then added; the maintenance medium contained
  • TPCK-treated trypsin at about 1.0 ⁇ g/ml.
  • the input dose of virus was 10 -2 -10 -3 PFU/cell.
  • the material for further passage was collected 72 hours postinfection (p.i.), with trypsin (final concentration, about 1.0 ⁇ g/ml) added at 48 hours p.i..
  • Cells were infected with serial 10-fold dilutions of virus, which were added to the washed cell monolayer without previous adsorption.
  • Virus accumulation was estimated by visual determination of the cytopathic effect (CPE) and HA titration of culture fluid at different times p.i. (24, 48 and 72 hours). Infectivity titrations were performed in 96-well plates.
  • Tissue culture infectious doses (TCID 50 /ml and egg infectious doses (EID) 50 /ml values were calculated by the formula of Karber [Arch, Exp. Path. Pharmak., Vol. 162, pp. 480-483 (1931).
  • Virus-containing culture fluids were concentrated in an Amicon system and purified by differential sedimentation through 25-70% sucrose gradients. Whole virus protein estimates were made by the method of Bradford (1976). To determine the yield of HA protein in virus grown in Vero and MDCK cells, the virus proteins were separated by gradient (4-20%) SDS-PAGE and intensity of Coomassie blue-stained protein bands was quantified by densitometry.
  • Influenza A viruses were isolated from the throat washings of patients with clinical signs of influenza and collected in PBS to which 0.7% BSA was added.
  • Cell culture both Vero and MDCK
  • embryonated chicken eggs were infected directly with freshly collected (not frozen) throat washings.
  • Chicken eggs were inoculated amniotically and allantoically.
  • Clinical samples used for isolation were inoculated undiluted and at 10 -1 and 10 -2 dilutions and incubated for 72-96 hours. Trypsin was added at 0 and 48 hours p.i. (about 1.0 ⁇ g/ml) and tested for virus replication with chicken and guinea pig erythrocytes. Each sample was given at least two passages in chicken eggs or cell cultures before being considered negative.
  • Monolayer antibodies to the A/Baylor/5700/82 (H1N1) and A/Baylor 11515/82 (H1N1) strains were prepared by the method of Köhler and Milstein (1976).
  • Polyclonal antisera to influenza A/England/ 1/53 virus (20 passages in Vero cells) were prepared in chickens by intravenous injection of virus-containing culture fluid.
  • HA and HI reactions were performed in microtiter plates with about 0.5% (v/v) chicken erythrocytes.
  • Guinea pig erythrocytes (about 0.4% v/v) were used to analyze primary influenza A isolates from the 1993-1994 winter epidemic season.
  • RNA was isolated by treating virus-containing allantoic or culture fluids with proteinase K and sodium dodecyl sulfate and then extracting the product with phenol-chloroform (1:1) and ethanol precipitation as previously described (Bean et al, 1980). Viral RNA was converted to cDNA with the use of U12 (5'AGCGAAAGCAGG3') and AMV reverse transcriptase.
  • U12 5'AGCGAAAGCAGG3'
  • AMV reverse transcriptase The sequences of the oligonucleotide primers used in this study for molecular characterization of internal genes (PB2, PB1, PA, NS and M) are available on request.
  • Amplification proceeded through a total of 35 cycles of denaturation at 95°C (1 min), annealing at 50°C (1 min), and primer extension at 74°C (3 min).
  • Amplified DNAs were analyzed by electrophoresis, visualized with ethidium bromide and then purified with either the MagicTM PCR Preps DNA purification system (Promega, Madison, WI) or the Geneclean ® kit (BIO 101, La Jolla, CA) according to the manufacturers' instructions.
  • Nucleotide sequencing was performed dideoxynucleotide chain termination method with the fmolTM DNA sequencing system (Promega). The reaction products were separated on 6% polyacrylamide-7M urea gels, 0.4 mm thick.
  • Vero and MDCk cell monolayers were infected with the Vero-adapted influenza virus strain A/England/1/53 [HG] at 10 -3 PFU/cell multiplicity of infection, trypsin (about 1.0 ⁇ g/ml) was included in the medium. Infected and control cell monolayers were fixed at 48 hours postinoculation in cacodylate-buffered 2.5% glutaraldehyde, post-fixed in 1% osmium tetroxide, dehydrated in graded series of alcohols and embedded in Spurr low-viscosity embedding medium (Ladd Research Industries, Burlington, VT).
  • trypsin about 1.0 ⁇ g/ml
  • Influenza viruses can replicate to high titers in a limited number of mammalian cells, provided that trypsin is present for cleavage of the HA molecule.
  • a virus repository was screened and a master strain was selected that would replicate sufficiently in the mammalian epithelial-like cell line.
  • MDCK cells which are widely used to isolate and culture viruses, were included in the study as a reference.
  • the influenza A virus strains that we examined had been isolated from a wide range of human and avian hosts, and represent 12 of the 14 HA (not H5 and H7) and 9 NA subtypes.
  • Viruses were passaged three times in Vero and MDCk cells, and the virus yield was estimated from HA and infectivity titers. Of the 72 strains investigated, 65 (90.3%) replicated to the level that can be detected by HA titration in Vero cells after the first passage and 37 (51.4%) after the second. By comparison, all strains could replicate in MDCK cells during the first and second passages.
  • Six humans and four avian influenza A viruses were selected as strains with the highest growth potential (Table 4), among which A/England/1/53 (H1N1) [HG] virus was chosen for further adaptation to Vero cells.
  • [HG] strain selected for adaptation to growth in Vero cells is a reassortant between the original A/England/1/53 strain and
  • A/PR/8/34 Six genes of the reassortant encoded internal proteins of A/PR/8/34 and two surface glycoproteins of A/England/1/53.
  • Viral protein yield is an important feature of any system used to produce influenza virus vaccines.
  • To establish the amount of virus-specific proteins that can be obtained from Vero cells we compared the protein yields of A/England/1/53 [HG] (20-passage) virus after replication in Vero and MDCK cells (Table 7). Determination of the HA protein yield was done using SDS-PAGE separated virus proteins and was quantitated by densitometry. Tests of culture fluids indicated that approximately 6 ⁇ 10 8 of infected cells could produce 4.38 mg of virus protein in Vero and 4.13 mg in MDCk cells. It was also possible to obtain viral proteins from disrupted virus-infected cells of either type; the protein yields were lower than in the supernatant but there was no significant difference between the cell types in the amount of virus protein.
  • MDCK cells provide the most sensitive host cell system for the primary isolation of influenza viruses.
  • Vero cells have been successfully used to isolate parainfluenza and mumps viruses, but they were judged unsuitable for the isolation of influenza viruses.
  • We tested nine clinical specimens collected during the 1993-1994 epidemic season in three culture systems (Vero and MDCK cells and embryonated chicken eggs).
  • Six influenza A (H3N2) strains were isolated in Vero cells, seven in MDCK cells and only two in embryonated chicken eggs (Table 9). Two samples failed to yield virus in any host system.
  • CPE observed 48-72 hours after inoculation was the only evidence of virus reproduction.
  • HA activity was detectable on the second passage, and, by the third passage, the positive samples produced both CPEs and HA titers that ranged from 2-32.
  • guinea pig erythrocytes it was necessary to use guinea pig erythrocytes to determine HA titers, chicken erythrocytes failed to be agglutinated as was first described by Burnet and Bull.
  • influenza A H2N2
  • virions were released from the apical surface of Vero cells, a feature typical of epithelial cells infected with influenza virus.
  • the budding virions in MDCK and Vero cells appeared filamentous.
  • a fraction of infected cells in both systems showed cytopathological changes indicative of apoptosis.
  • the nuclear changes included fragmentation and condensation of chromatin, margination of chromatin to the nuclear envelope, and blebbing of the nuclear envelope.
  • the cytoplasmic changes consisted of condensation, extensive vacuolation, and blebbing and vesiculation of the plasma membrane to form "apoptotic bodies.”
  • the histochemical assay consisted of addition of digoxigenin-labeled nucleotides to the 3'-OH ends of broken DNA with use of terminal deoxynucleotidyl transferase and detection of the added nucleotides by reactivity with fluorescein-labeled antidigoxigenin antibodies.
  • the infected Vero and MDCK cells showed 20% and 30% positive cells, respectively, by this assay, whereas the uninfected cells were negative.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Seasonings (AREA)

Abstract

Le procédé décrit est destiné à la réplication du virus de la grippe humaine selon une faible multiplicité d'infection dans une lignée cellulaire Véro. Ce procédé consiste à maintenir une concentration de trypsine d'au moins 0,05 νg/ml dans le milieu de culture pendant tout le cycle de croissance du virus.
PCT/US1995/014814 1994-11-16 1995-11-13 Nouveau procede de replication WO1996015232A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU41589/96A AU694592B2 (en) 1994-11-16 1995-11-13 Novel replication process
JP8516287A JPH11509081A (ja) 1994-11-16 1995-11-13 新規の複製プロセス
EP95939952A EP0808361A4 (fr) 1994-11-16 1995-11-13 Nouveau procede de replication
NZ296861A NZ296861A (en) 1994-11-16 1995-11-13 Replicating human influenza virus in a vero cell culture involving maintaining consistent minimum concentration of trypsin in the culture medium
NO972239A NO972239L (no) 1994-11-16 1997-05-15 Ny replikasjonsprosess
CA002205677A CA2205677A1 (fr) 1994-11-16 1997-05-16 Nouveau procede de replication

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34025494A 1994-11-16 1994-11-16
US08/340,254 1994-11-16
CA002205677A CA2205677A1 (fr) 1994-11-16 1997-05-16 Nouveau procede de replication

Publications (1)

Publication Number Publication Date
WO1996015232A1 true WO1996015232A1 (fr) 1996-05-23

Family

ID=25679347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/014814 WO1996015232A1 (fr) 1994-11-16 1995-11-13 Nouveau procede de replication

Country Status (6)

Country Link
EP (1) EP0808361A4 (fr)
JP (1) JPH11509081A (fr)
AU (1) AU694592B2 (fr)
NO (1) NO972239L (fr)
NZ (1) NZ296861A (fr)
WO (1) WO1996015232A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0895535A1 (fr) * 1996-04-05 1999-02-10 St. Jude Children's Research Hospital Replication du virus de la grippe dans une culture de cellules de mammifere et production de vaccin
US6455298B1 (en) 1996-04-01 2002-09-24 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
US7883844B2 (en) 2006-05-11 2011-02-08 Juridical Foundation The Chemosero-Therapeutic Research Institute Method for propagating influenza virus
WO2011134660A1 (fr) 2010-04-28 2011-11-03 Abbott Biologicals B.V. Production de composants viraux
CN102586195A (zh) * 2011-12-01 2012-07-18 哈药集团生物疫苗有限公司 一种利用Vero传代细胞制备禽流感病毒及其灭活疫苗的方法
US8278433B2 (en) 2005-06-21 2012-10-02 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
DE19655440B4 (de) * 1996-04-01 2013-09-05 Novartis Vaccines And Diagnostics Gmbh Verfahren zur Herstellung eines Influenzaimpfstoffs
US10329536B2 (en) 2001-09-12 2019-06-25 Seqirus UK Limited Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319864T3 (es) 2000-04-28 2009-05-14 St. Jude Children's Research Hospital Sistema de transfeccion de adn para la generacion de virus infecciosos de arn de cadena negativa.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1122527A (fr) * 1979-05-15 1982-04-27 Karen K. Brown Production d'un vaccin contre l'influenza par culture de cellules en milieu liquide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0808361A4 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455298B1 (en) 1996-04-01 2002-09-24 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses
US6656720B2 (en) 1996-04-01 2003-12-02 Chiron Behring Gmbh & Co. Animal cells and processes for the replication of influenza viruses
DE19655440B4 (de) * 1996-04-01 2013-09-05 Novartis Vaccines And Diagnostics Gmbh Verfahren zur Herstellung eines Influenzaimpfstoffs
EP0895535A1 (fr) * 1996-04-05 1999-02-10 St. Jude Children's Research Hospital Replication du virus de la grippe dans une culture de cellules de mammifere et production de vaccin
EP0895535A4 (fr) * 1996-04-05 2004-09-15 St Jude Childrens Res Hospital Replication du virus de la grippe dans une culture de cellules de mammifere et production de vaccin
US10329536B2 (en) 2001-09-12 2019-06-25 Seqirus UK Limited Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture
US8278433B2 (en) 2005-06-21 2012-10-02 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
US8742089B2 (en) 2005-06-21 2014-06-03 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US7883844B2 (en) 2006-05-11 2011-02-08 Juridical Foundation The Chemosero-Therapeutic Research Institute Method for propagating influenza virus
WO2011134660A1 (fr) 2010-04-28 2011-11-03 Abbott Biologicals B.V. Production de composants viraux
CN102586195A (zh) * 2011-12-01 2012-07-18 哈药集团生物疫苗有限公司 一种利用Vero传代细胞制备禽流感病毒及其灭活疫苗的方法

Also Published As

Publication number Publication date
AU694592B2 (en) 1998-07-23
NO972239D0 (no) 1997-05-15
AU4158996A (en) 1996-06-06
NO972239L (no) 1997-07-16
JPH11509081A (ja) 1999-08-17
EP0808361A1 (fr) 1997-11-26
NZ296861A (en) 1998-05-27
EP0808361A4 (fr) 2001-07-18

Similar Documents

Publication Publication Date Title
US5824536A (en) Influenza virus replicated in mammalian cell culture and vaccine production
Kaverin et al. Impairment of multicycle influenza virus growth in Vero (WHO) cells by loss of trypsin activity
Lazarowitz et al. Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide
Scheid et al. Protease activation mutants of Sendai virus: Activation of biological properties by specific proteases
Govorkova et al. African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses
ES2367081T3 (es) Procedimiento para la replicación de virus de la gripe en cultivo celular y los virus de la gripe que pueden obtenerse por el procedimiento.
Nagai et al. Molecular biology of Newcastle disease virus
US6455298B1 (en) Animal cells and processes for the replication of influenza viruses
Govorkova et al. Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero)
WO1997038094A9 (fr) Replication du virus de la grippe dans une culture de cellules de mammifere et production de vaccin
Herrler et al. Structure and function of the HEF glycoprotein of influenza C virus
Giraudon et al. Antigenic analysis of African measles virus field isolates: identification and localisation of one conserved and two variable epitope sites on the NP protein
AU694592B2 (en) Novel replication process
JP2003516733A (ja) ワクチンの生成方法
Rudneva et al. Phenotypic expression of HA-NA combinations in human-avian influenza A virus reassortants
Muramatsu et al. Trypsin Action on the Growth of Sendai Virus in Tissue Culture Cells: V. An Activating Enzyme for Sendai Virus in the Chorioallantoic Fluid of the Embryonated Chicken Egg
Yamnikova et al. A reassortant H1N1 influenza A virus caused fatal epizootics among camels in Mongolia
CA2744354A1 (fr) Procede pour la production de virus a enveloppe stables au ph
Nerome et al. Absence of neuraminidase from influenza C virus
Noma et al. Endogenous protease-dependent replication of human influenza viruses in two MDCK cell lines
Slosaris et al. Elevated virulence of Newcastle disease virus strains following serial passages in kidney cells in vitro
CA2205410A1 (fr) Nouveau procede de replication
Kendal et al. Comparative studies of wild-type and “cold-mutant”(temperature-sensitive) influenza viruses: Polypeptide synthesis by an Asian (H2N2) strain and its cold-adapted variant
CA2205677A1 (fr) Nouveau procede de replication
CN113423422A (zh) 增殖方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WA Withdrawal of international application
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 296861

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995939952

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2205410

Country of ref document: CA

Ref country code: CA

Ref document number: 2205410

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 516287

Kind code of ref document: A

Format of ref document f/p: F

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 1995939952

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1998 97712

Date of ref document: 19980616

Kind code of ref document: A

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1995939952

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载